<SEC-DOCUMENT>0001104659-12-006943.txt : 20120206
<SEC-HEADER>0001104659-12-006943.hdr.sgml : 20120206
<ACCEPTANCE-DATETIME>20120206170844
ACCESSION NUMBER:		0001104659-12-006943
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120206
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120206
DATE AS OF CHANGE:		20120206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		12574423

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a12-4320_18k.htm
<DESCRIPTION>CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, DC 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>&#160;February&nbsp;6, 2012</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Orthofix International N.V.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of Registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Curacao</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-19961</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7 Abraham de Veerstraat</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Curacao</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>011-59-99-465-8525</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106748\12-4320-1\task5086130\4320-1-ba.htm',USER='106748',CD='Feb  6 22:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 7.01.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Regulation FD Disclosure</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On February&nbsp;6, 2012, Orthofix International N.V. (the &#147;Company&#148;) issued a press release regarding the status of certain legal matters.&#160; A copy of the press release is furnished as Exhibit&nbsp;99.1 to this Form&nbsp;8-K.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information included in this Current Report on Form&nbsp;8-K under this Item&nbsp;7.01 (including Exhibit&nbsp;99.1) shall not be deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Financial Statements and Exhibits</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exhibits</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Press Release, dated February&nbsp;6, 2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_224155_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106748\12-4320-1\task5086130\4320-1-ba.htm',USER='106748',CD='Feb  6 22:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V.</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Brian McCollum</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Brian   McCollum</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Senior Vice President of Finance</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   February&nbsp;6, 2012</font></p>    </td>
<td width="25%" valign="top" style="padding:0in 0in 0in 0in;width:25.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_224324_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106748\12-4320-1\task5086130\4320-1-ba.htm',USER='106748',CD='Feb  6 22:56 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:8.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:88.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release,   dated February&nbsp;6, 2012</font><font size="2" style="font-size:10.0pt;">.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_224358_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106748\12-4320-1\task5086130\4320-1-ba.htm',USER='106748',CD='Feb  6 22:56 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a12-4320_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt .5in;text-align:right;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="407" height="64" src="g43201mmi001.jpg" alt="GRAPHIC"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Orthofix International Moves to Resolve U.S. Government Legal Matters</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LEWISVILLE, Texas - February&nbsp;6, 2012 (BUSINESS WIRE) - Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has made significant progress in resolving several outstanding legal matters with the U.S. Government. These highlights include:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Reaching an agreement in principle to resolve the U.S. Government investigation of Blackstone Medical,&nbsp;Inc.</font></i></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Reaching an agreement in principle with the U.S. Department of Justice to settle violations of the Foreign Corrupt Practices Act.</font></i></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Finalizing definitive agreements to resolve criminal and civil matters related to the U.S. Government investigation of its bone growth stimulation business.</font></i></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;I am very pleased with the substantial progress made regarding these three legal matters, which removes a significant amount of risk and uncertainty for th</font><font size="2" style="font-size:10.0pt;">e Company,&#148; said President and Chief Executive Officer Robert Vaters. &#147;Orthofix has made significant improvements to its compliance practices, personnel, and financial standing to provide a strong foundation from which to grow. I look forward to a stronger focus on the Company&#146;s operations, including investments in R&amp;D to position the Company for long-term growth, while maintaining earnings improvement.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement in Principle Reached for Blackstone Medical,&nbsp;Inc.</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has reached an agreement in principle with the U.S. Attorney&#146;s Office for the District of Massachusetts to pay $32 million to resolve matters related to the investigation of the Company&#146;s subsidiary, Blackstone Medical,&nbsp;Inc. (&#147;Blackstone&#148;).&#160; The settlement will be funded by proceeds received by the Company from the escrow fund established in connection with the agreement and plan of merger between the Company and Blackstone in 2006 and includes resolution of a qui tam complaint filed by Susan Hutcheson against Blackstone and the Company in the U.S. District Court for the District of Massachusetts.&nbsp; In addition, the Company resolved remaining escrow claims with the former equity holders of Blackstone. As a result of the settlement, the Company will receive approximately $9 million in cash and take a charge of approximately $6.0 million during the fourth quarter 2011 for previously incurred legal fees. The final settlement is subject to the negotiation and&#160; approval of definitive agreements with the U.S. Attorney&#146;s Office, the U.S. Department of Justice (&#147;DOJ&#148;), and the Office of Inspector General of the U.S. Department of Health and Human Services (&#147;OIG&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\12-4320-1\task5086538\4320-1-mm.htm',USER='105344',CD='Feb  7 01:34 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement in Principle Reached with the DOJ for Foreign Corrupt Practices Act Matter</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company also reached an agreement in principle with the DOJ to settle criminal violations of the Foreign Corrupt Practices Act (FCPA) that it voluntarily reported to the U.S. Government in June&nbsp;2010 concerning its former Mexican orthopedic distribution entity.&nbsp;In the first quarter 2011 financial results, the Company reported that it had recorded a charge of $3.0 million to establish an accrual in connection with this matter based on the results of its own internal investigation and an analysis of similar FCPA resolutions.&#160; As the result of recent discussions with the DOJ and staff at the U.S. Securities and Exchange Commission, the Company plans to take a charge of approximately $4.5 million in the fourth quarter 2011 to establish as an additional accrual in anticipation of a proposed criminal and civil resolution of this matter.&nbsp; Final resolution is subject to the negotiation and execution of definitive agreements with the DOJ.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Finalizing Definitive Agreements for Bone Growth Stimulation Matters</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is also finalizing definitive agreements with the U.S. Attorney&#146;s Office, the DOJ, and the OIG to resolve criminal and civil matters related to an investigation of its bone growth stimulation business, which includes resolution of a qui tam lawsuit pending in the U.S. District Court for the District of Massachusetts. &nbsp;Under the terms of the agreements, the Company will pay the U.S. Government $43 million, a charge previously disclosed and already accrued by the Company in the first quarter 2011.&nbsp; &#160;Orthofix Inc., a subsidiary of the Company, expects to plead to a violation of 18 USC 1516, related to an obstruction of a June&nbsp;2008 federal audit.&nbsp; The Company and Orthofix Inc. also expect to enter into a five-year Corporate Integrity Agreement (CIA) with the OIG as part of the resolution of these matters.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In summary, as a result of the matters described above, the Company expects a pre-tax impact of approximately $10.5 million to its fourth quarter 2011 financial results and expects to receive cash of approximately $9 million from the Blackstone escrow fund. The Company had previously obtained an amendment to its current credit facility to provide additional capacity under the various restrictive covenants for these charges by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Orthofix:</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix&#146;s products are widely distributed around the world to orthopedic surgeons and patients via Orthofix&#146;s sales representatives and its subsidiaries, including BREG,&nbsp;Inc., and via collaborations with other leading orthopedic product companies.&#160; In addition, Orthofix is collaborating on R&amp;D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Texas Scottish Rite Hospital for Children, and the Cleveland Clinical Foundation.&#160; For more information about Orthofix, please visit www.orthofix.com.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\12-4320-1\task5086538\4320-1-mm.htm',USER='105344',CD='Feb  7 01:34 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements:</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995.&#160; These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management&#146;s current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The forward-looking statements in this release do not constitute guarantees or promises of future performance.&#160; Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the expected sales of our products, including recently launched products, unanticipated expenditures, the resolution of pending litigation matters (including the government investigation and False Claims Act matters relating to our bone growth stimulation and spinal implant businesses, and the possible violations of the FCPA by our former Mexican orthopedic distribution entity, as well as certain product liability claims against our sports medicine global business unit), changing relationships with customers, suppliers, strategic partners and lenders, changes to and the interpretation of governmental regulations, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry, credit markets and the economy, corporate development and market development activities, including acquisitions or divestitures, unexpected costs or operating unit performance related to recent acquisitions, and other factors described in our annual report on Form&nbsp;10-K and other periodic reports filed by the Company with the Securities and Exchange Commission (SEC).&#160; Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.&#160; The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company cannot predict the timing or outcome of ongoing litigation matters and governmental investigations of our businesses which could result in civil or criminal liability or findings of violations of law (as further described in the &#147;Legal Proceedings&#148; sections of our annual report on Form&nbsp;10-K and quarterly reports on Form&nbsp;10-Q), that could materially impact our financial position and/or liquidity.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mark Quick</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director of Investor Relations and Business Development</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">markquick@orthofix.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">214-937-2924</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Source</font></u></b><font size="2" style="font-size:10.0pt;">:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Orthofix International N.V.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\pselva\12-4320-1\task5086538\4320-1-mm.htm',USER='105344',CD='Feb  7 01:34 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g43201mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g43201mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!``9<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:HKFY@LX
M&GN9DAB099W;`%2,"5(4X/8D9K#U#PCIVKN'U22YNV'0/,55?HJX`JHJ-_>9
M,G)+W4<UK_Q0ABW6^AQ><_3[1*,(/H.I_'%>>W^K:AJDS2WUY-.S'.&8X'T'
M05Z-??#+1[V%Y-'O7A=25P7\R/(['N/SKSW6-%O]"O3:W\)C;JK#E7'J#WKV
M,,Z&T-_/<\7%*OO/;RV*L%S<6LGF6T\L+_WHW*G]*Z_P_P#$G4;"18=5)O;;
MH7_Y:I[Y_B_'\ZXNBNF=.%16DCEIU9TW>+/H>QOK;4K..[LYEFAD&59?\]:L
M5XQX%\4/H.JK;3N?L%TP60'I&W9A_7_ZU>S5X=>BZ4K=#WL/75:%^HM%%(2`
M"2<`=36!T"T5S6I_$/PEI#M'=:Y;>8O5(B9"/^^<XK&/QI\%@X%W<GW%LU`'
M?45P]M\8?!5P^TZE)#[RV[@?H#74:5KVD:W'YFEZE;78'412`D?4=10!H444
M4`%%96I^)]"T5MNI:O:6K_W))0&_+K6.?BEX)!(.OP\>D<A_]EH`ZVBN37XI
M>"68`:_#D^L<@_\`9:V],\0:-K0SIFIVMWCJ(I0Q'U'6@#1HK&USQ=H/AJ6*
M+6-12T>92T89&.X#KT!K+_X6GX(_Z#\7_?J3_P")H`ZVBN2_X6GX(_Z#\7_?
MJ3_XFC_A:?@C_H/Q?]^I/_B:`.MHKDO^%I^"/^@_%_WZD_\`B:O:1XX\-:]=
M/:Z7JL=S-'&9614<848R>0/44`;]%<E_PM/P1_T'X?\`OU)_\370Z7JMCK6G
M1:AIUPMQ:S9V2*"`V"0>O/4&@"Y1165KGB?1O#4<,FL7R6BSDB,LK'<1UZ`^
MM`&K17-:=\0_">JW\-A8ZS'-<SMMCC$;@L?Q7%=+0`45EZMXET30AG5=4MK0
MD9"22#<?HO4US,_QD\%0N4&H32X[QV[D?J!0!W5%<$GQH\%LP!O+E?<VS8K<
MTKQYX5UEUCL=;M7D;I&[>6Q^@;&:`.AHHHH`**K7NHV.FP^=?7D%K'_>FD"#
M]:P)OB7X+MVVOX@M2?\`8W/_`.@@T`=117)?\+3\$?\`0?B_[]2?_$T?\+3\
M$?\`0?B_[]2?_$T`=;16"/&_ALZ&=;&JQ_V>)?),^Q\;_3&,_I5`?%+P22`-
M?AR?^F4G_P`30!UM%8>M>,_#WAZ>*'5M16U>9-\>Z)R&'L0"*HP?$SP9<W$<
M$6O0&21@JAD=02>G)7`H`ZJBDI:`"BN8O/B1X/L+R6TN==@2:%BCJ$=L$=1D
M`BI]+\=>&=:FDBT[58YVAC,DA\MU5%'4EB``/J:`.@HK.M-?TR^N%@@N3YD@
M+1J\;IY@'7:6`W?AFB@"KKOBW2?#Z$74^^?'RV\7S.?\/QKS/Q!X^U;6MT,+
MFRM3QY<3?,P_VF_PKFI97GGDFD8L\C%F8]R:97N4<+"GJ]6>#6QE2IHM$>Q_
M#5@?!T(':60'Z[JVM=T.T\0:8]E=KUYCD`^:-NQ%<C\)[\/IU[I[-\T4HE4>
MS#!_4?K7H%>77O"LVNYZN'M.@D]K'SUJ6G7&DZC/872[986P?0CL1[$55KTS
MXJ:,KVUOK,2X>,^3,0.JG[I_`\?C7F=>S0J>T@I'B5Z7LJCB!&:]M\"ZLVK>
M%K:25MTT&89">I*]#^6*\2KTKX2SDP:G;GH'1Q^((/\`(5AC8WI7[&^!FU5M
MW/0V940N[!549))X`KYR^(?Q+U#Q/J$UEI]P]OI$;%41#M,_^TQ[@]ATKVKX
MB7DEC\/]9GB)#_9B@([;B%_K7RQ7BGNF]X3\&:OXQOFM],B41QX,UQ(<1Q@^
MI[GV%>FVO[/]L(A]KU^5I._E0``?F:['X5:9#IOP]TTQ*`]TAN)6_O,Q_P`,
M#\*["@#PK7/@/J-I;O/HVIQWQ49\B6/RW;V!R03]<5YC%-?Z-J.^*2>SO+=\
M94E'1AU'M7V'7SQ\;],BL?'"7,2JOVVV65P.[`E2?R`H`]&^%7Q!D\6V,NGZ
MD5_M.T4,7`QYR=-V/4'@_45A?%_XB7NEW7_".:-.8)=@:ZN$.&7/1%/;CDGW
M%<'\)KR2T^(VF!#@3EXG'J"I_J!6;X^N&NO'FM2MG/VQUY]%.T?RH`S--TS4
MO$&II9V$$MW=S'(4<D^I)/0>YKT:S^`FNS1*]WJEE;,>J*&D(_'@5F?#'QQH
M7@I+Z;4+.YFN[DJJ/"JG:@[<D=3_`"%=[_POGPU_T#]2_P"^$_\`BJ`.1OO@
M/X@M[=I+34+*[=1D1_,A;Z9&*\WBEN],OM\,DEM=6[X#(Q5D8'U%>UZA\?=,
M6W<:;H]U)-CY#.RHH/O@DUXE-++>WDDK#?-/(6(4=6)[#ZF@#U]?#VH?&+PU
MI.JR:C%:W5BLEM<%XB?,8$$,,=,C&?>J_P#PS_J'_0?MO^_#?XUW_P`+/#UU
MX<\$6]M?(8[FX=KAXSU3=C`/O@#-=C0!\K>-_!TW@K5H=/GO([II81+O1"H'
M)&.?I5?PAX:E\6^((M(AN4MGD1F$CJ6`VC/05V?QY_Y'"S_Z\E_]#:LSX,?\
ME'M/^N,O_H!H`Z'_`(9_U#_H/VW_`'X;_&NB\%?"VZ\%ZG=ZG/JD-TKV4D.Q
M(BI!)!SDG_9KTZH;S_CRG_ZYM_*@#XY;[Q^M?37PD_Y)II/TE_\`1KU\RM]X
M_6O3/"7QB;POX:M-&&B"Y^S;OWOVC;NW,6Z;3ZT`?0%>0_M`_P#(-T7_`*[2
M_P`EJK_PT$W_`$+@_P#`O_[&N1\?_$8^.;:RA.F"S^RNS9\[?NR`/0>E`%'X
M9_\`)1=%_P"OC_V4UZK\6?B-<>'`FB:/($OYDWS3#DPH>@'^T?T'UKRKX9_\
ME%T7_KX_]E-0>/[R2^\>:U-(22+MXQGL%.T?H*`,B**_UK4DBC$UY>7+X49+
M/(QKU/1O@'>30++K.KI:NPR8;>/S"OU8D#\LU!\!-,AN->U'4I$#26D*I%G^
M$N3D_DN/Q->[4`>.7G[/\/E$V.ON)!T$\`(/X@\5Y=XF\*ZKX2U/[#JD(1F&
MZ*5#E)5]5/\`3J*^M*\^^->FQ7G@*2Z9`9;*9)$;N`3M(_'/Z4`>?_#'XFWN
MCZE;Z-J]R\^F3L(T>1LM;L>A!_NYZCMUKU[QWXK3P?X8GU+:KW#$16\;=&D/
M3/L`"?PKY6Z5ZC\6M6FO_"WA`2$YGL_M#\]6*(/ZF@#SS5-7U+7]0:[U&ZEN
M[B0]6.<>P'8>PKN=%^"'B34[5+B]FM]-5QD1RY:0#W`Z?3-<;X8U2TT7Q)9:
MG>VK74-K)YAB4@%B!\O7T.#^%>N?\-`:;_T`KK_O\O\`A0!FC]GZZP,^(H<]
M\6I_^*I?^&?KG_H8HO\`P%/_`,56C_PT!IO_`$`KK_O\O^%;_@SXJ6?C+6SI
M<&F3VSB%I=[R!A@$#''UH`Y7QEX4?P;\''TJ2[6[/]HK+YBIL'/;&3Z5XW#_
M`*Y/]X?SKZ(^-W_)/F_Z^XOZU\[P_P"N3_>'\Z`/JWQ%X7T[Q;X>_LW4$ZH#
M%,!\T+XX8?X=Z^9_$_AG4?">LR:;J,>&7F.4#Y94[,O^>*^L8/\`CWC_`-P?
MRK#\8^$-/\8Z,UC>+LE3+6\X'S1-Z^X]1WH`\^^$OQ+-P(?#6N3_`+T`+9W+
MG[X[1L?7T/?IZ5=^+'Q*&D12>']%G_T^08N9T/\`J%/\(/\`>/Z?7IXQKFBW
M_AG6IM,OE\NYMV'*-P1U#`^XYJ"RM+O6=5AM(3YMU=RA%,CXW,QZDGW[T`6-
M`T'4/$VL1:9IT1DGE.23T1>[,>P%?1%AX*M?"OA*.QT^`W3I/%/>$+\]UM8%
MACOP.%]L=ZM>!?`]EX*T@01;9KV8`W-SCESZ#T4=A^-=10!Y#::'>7<=W:V4
MOVJ\NX\Q/&&06S><SMYA(')0A03S\Q7&.:*]>HH`^>]5M#8:Q>69&/)F=!]`
M>/TJI7;_`!/T8VFM1ZI&O[J\7#D#I(H_J,?D:XBOHJ4^>"D?-5H>SJ.)M>$]
M<_X1_7X+MR?(;]W.!_</?\#@_A7N:.LD:R(P9&`*L#P0>]?.5=_X"\;I9*FC
MZK+M@Z6\['A/]EO;T/:N3&4'-<\=T=F"Q"@^26S.Z\4V8O\`PQJ-N1G,#,/J
M!D?J*\&'2OH:_9?[,N6)RODL<@]MIKYY'05.`?NR168I<T6%>D_"2!O*U.X.
M=I9$'U`)/\Q7FU>W>"-&;1?#,$,J[9YLS2CT+=!^`Q6N-FE2MW,<#!RJW[#_
M`!QILFK^"=7L85W2R6S%%'=E^8#\Q7RC7V97B/Q$^$%Y]NFUCPU#Y\,S%Y;)
M>&1CU*>H]NH[5XI[IV?P@UZWU;P-:VBR#[3IV8)4SR!DE3]"/Y&N[KY'L-1U
MOPGJGGVLESIUY'P0RE21Z,IZCV(KM[7X[>)X8@L]II]PP_C:-E)_)L4`?0-?
M-OQ@UZ#7/&\B6L@DAL8A;AU.0S`DMC\3C\*CUWXN>+-<MGM3=1V4$@(9;5-I
M8>FXDG\B*P]!\(:]XEG6/3-.FE4G!F9=L:_5CQ0!O?![39;_`.(=G*BG99H\
M\A'8;2H_5A6#XS_Y'76O^OZ;_P!#-?0WP_\``EMX)TIH]ZSWUQ@W$X&`<=%7
MV'ZU\[^,'$GC/6F'3[?-_P"AF@#L?AE\.-*\::1>7>H7-W"\$XC40,H!&T'G
M(/K792?`7PZ8V$>I:BKD':69"`>V1MYJ+X!?\BWJ?_7X/_0!7JU`'R)K^A7W
MAO69]+U"/9-"W4='7LP]0:]2^"=[X9N'-E/IEM%KD.6BN'&YIE_V<]&'MV_&
MNU^)/@2+QEHV^W54U2U4FWD/&\=T)]#V]#^-?.$4M[HVIK)&TEI>6DO!^ZT;
MJ?\`&@#[#HKD?AYXZM_&>C!G*1ZE;@+<PCC/^VH_NG]#Q774`>`_'G_D<+/_
M`*\E_P#0VK,^#'_)1[3_`*XR_P#H!K3^/)_XK&S'_3BO_H;5F?!C_DH]G_UQ
ME_\`0#0!](U#>?\`'E/_`-<V_E4U0WG_`!Y3_P#7-OY4`?'+?>/UKW'X>?#;
MPKKW@C3]3U'3VENIQ)YCB=USB1@.`<=`*\./WC]:^F?A(<_#/2?I+_Z->@"/
M_A3_`((_Z!3_`/@3)_C7G?Q>\%Z#X5LM,DT>T:!KB219"96?(`&.I/K7O=>0
M_M`_\@W1?^NTO\EH`\Y^&?\`R471?^OC_P!E-)\2=-DTOQ_JT3H566<SH?57
M^;/ZD?A2_#3_`)*+HO\`U\?^RFO;?B/\/(?&EDEQ;.L&J6RD12-]V1>NQOZ'
MM^-`'FWP.UV#3?%%SIMRX0:C$%B).`9%.0/Q!-?0%?)&L>&]<\-W7EZEI]Q:
M.C?+)M.TD=U8<'\#74:/\9?%NE0)!+-!?QH,`W2$OC_>!!/XYH`^CZ\S^..N
MV]EX431Q(#<W\JG8#R(U.23^(`_/TKA[WXY^*;B(I;P6-H2,;TB+$?3<2/TK
MB)7UKQ3JK3.+K4KV8\D*78_ET'Z4`9\:/+(L:*6=R`JCJ2:]+^,5BVEVGA6P
M;[UMIWE'ZKM!_E70?#7X2W&G7T.N^(XU26$[[>SR&*MV9STR.P]?RK/_`&@/
M^0KHW_7"3_T(4`<+X!T:R\0>,[#2]01GMIR^\(VTG"$CGZBO;/\`A2W@O_GU
MNO\`P):O(?A,?^+E:3_O2?\`HMJ^G*`.!_X4MX+_`.?6Z_\``EJU?#GPZ\.^
M%M3.HZ7!,DYC,>7F+#:2">#]!74T4`>>_&[_`))\W_7W%_6OG>'_`%R?[P_G
M7T1\;O\`DGS?]?<7]:^=XN)D)_O"@#[&@_X]X_\`<'\JXSXB_$6U\&V1MK4I
M/JTZ_NHCR(A_?;^@[TWQY\0[3P;I"00,D^K31#R8<Y\L8^^_MZ#O7SO--J&N
MZLTLK2WE]=R<G[S2,>U`$L,6J>)]<$:>;>ZA>R]2<L['J3[?R%2^(O#FI>%-
M8?3M1CV3)AD="=KKV93_`)Z5[[\-?AY#X/T_[7>*LFKW"_O7ZB%?[B_U/>M/
MQWX*M/&FB-;2;8KR'+6MQC[C>A_V3W_/M0!R7PJ^)HUB.+0-;F`OT&VWG<_\
M?`_NG_:_G]>OJE?'U_8WVB:I+9W<;VUW:R889P58="#^H->[_"[XF)XB@31M
M8F"ZK&N(Y&X%RH_]F]1WZ^M`'I5%%%`&=KVC0:]I$VGS\!QE'[HPZ&O"]2TZ
MZTF_EL;R,QS1'!]".Q'J#7T+6-XB\+Z?XDMA'=J4F0?NYT^\G^(]J[,-B/9.
MTMCBQ6&]JKQW/":UM$\,ZKX@DQ96Q\K.&GD^6-?Q[_05Z%HGPQTZQE\[4IC?
MN#\J;=L8^H[_`,J[1$C@B"1JL<:#A5&`HKJJXY+2GJ<E'`-ZU-#C+ZTE\'>`
M+R"?4I;N21/*CW_=0MQA>^.2>O:O)T1I'6.-6=V.%51DG\*]6\0:1J?C;48H
M8B;/2+8Y$T@^:9N[*O<=@3[UO:%X4TGP^@^R6X:?'S3R?,Y_'M^%13Q$:4&Y
M:R9I4P\JTTHZ11QO@SP!<B[CU+6H?*CB(:*V;[S-V+#L!Z5Z9117#5JRJRO(
M[J-&-*/+$****R-BO=6%G?+MO+2"X7TEC#_SK+?P3X5D8L_AS3"3U)M4_P`*
MW**`,FV\*>';-MUMH6GQ'U2V0'^5:JJJ*%50JC@`#`%+10`53?2=-D=G?3[5
MF8Y+&%22?7I5RB@"&WM;:T4K;6\4*DY(C0*"?PJ:BB@`JI)I>G32-)+86TCL
M<LS0J2?QQ5NB@"O!I]E:N7M[."%R,%HXPIQ^`JQ110!7GL+*Z</<6D$S`8#2
M1AB!^-)#IMC;2"6"RMXG'1DB53^8%6:*`"D(!&",@TM%`%+^QM+_`.@;:?\`
M?A?\*M0PQ6\0BAC2*->B(H`'X"GT4`%0W%I;7847-O%,%Z"1`V/SJ:B@"K%I
M>GPR+)%86T;KR&6%01^.*M444`-DC25"DB*Z-P589!K)N/"/AN[;=<:#ITC>
MK6J?X5L44`8<?@KPM$VY/#NF*P[BU3_"M:VM+:S39:V\4"?W8D"C]*FHH`*@
MN+&TNRIN;6&8KP#)&&Q^=3T4`58M,T^WD$L-C;12+T9(E!'X@5:HHH`****`
M(Y[>"YC\NXACF3.=LBAA^1JM_8^E_P#0-M/^_"_X5=HH`JS:;87$ADGL;>5S
MP6>)2?S(HBTO3X)%DBL+:-UY#)"H(_'%6J*`"BBB@"M-IUC<R&2>RMY7/&YX
@E8_F138]*TZ*19(["U1U.5985!!]CBK=%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
